# Blank Bio landing-page Growth Score report

Lazyweb publishes a public search API over its indexed pages; the guide is at https://www.lazyweb.com/agent-access.

Source: https://www.lazyweb.com/yc-s25/blank-bio
Source observed: 2026-10-17T10:27:33.649Z
Last checked: 2026-10-17T10:27:33.649+00:00
Indexed: 2026-10-17T14:10:18.427+00:00

---

[← Back to YC S25](https://www.lazyweb.com/yc-s25)

# Blank Bio

[http://blank.bio/](http://blank.bio/)

We evaluated Blank Bio’s landing page using Lazyweb’s Growth Score framework. The report identifies **Trust** as the weakest category.

## Overall score and ranking

- **Growth score:** **62 of 100**
- **Updated:** September 22, 2026
- **Weakest category:** Trust, scored **48**
- **YC S25 ranking:** #3 among the listed companies

### How Blank Bio ranks overall

1. [Ocean Genomics — 65](https://www.lazyweb.com/growth-score/site/oceangenomics.com)
2. [BostonGene — 65](https://www.lazyweb.com/growth-score/site/bostongene.com)
3. Blank Bio — 62
4. [SOPHiA GENETICS — 58](https://www.lazyweb.com/growth-score/site/sophiagenetics.com)
5. [Caris Life Sciences — 56](https://www.lazyweb.com/growth-score/site/carislifesciences.com)

[Fix Trust](https://www.lazyweb.com/plans/checkout?plan=individual&source=growth_score_feature_build_fixes)

## Category scores

- [Trust — 48](https://www.lazyweb.com/yc-s25/blank-bio#gs-trust)
- [CTA — 62](https://www.lazyweb.com/yc-s25/blank-bio#gs-cta)
- [Mobile web — 62](https://www.lazyweb.com/yc-s25/blank-bio#gs-mobile_web)
- [Value props — 68](https://www.lazyweb.com/yc-s25/blank-bio#gs-value_props)
- [Information hierarchy — 72](https://www.lazyweb.com/yc-s25/blank-bio#gs-information_hierarchy)

## Score over time

The report records these historical observations:

1. **September 22, 2026 — 62, live:** Overall −2; Mobile web −6; Information hierarchy +4.
2. [**September 14, 2026 — 64**](https://www.lazyweb.com/growth-score/history/2026-09-14): Overall +3; Mobile web +10; CTA +8.
3. [**June 17, 2026 — 61**](https://www.lazyweb.com/growth-score/history/2026-06-17): CTA −4; Trust +4.
4. [**May 19, 2026 — 61**](https://www.lazyweb.com/growth-score/history/2026-05-19): Overall −7; Mobile web −24; Information hierarchy −8.
5. [**April 19, 2026 — 68**](https://www.lazyweb.com/growth-score/history/2026-04-19): First tracked report; strongest category was Mobile web at 82 and weakest was Trust at 48.

## Trust — 48, Poor

Trust measures proof that a product is real, competent, and safe to try.

![Blank Bio trust capture](https://zlfyzdmohcskkucuunmk.supabase.co/storage/v1/object/public/sites/growth-score/site/blank.bio.jpg?v=2026-09-22T20%3A34%3A28.322%2B00%3A00)

The report compares Blank Bio with other companies’ visible trust signals:

| Company | Trust read |
| --- | --- |
| Blank Bio | News banner: “Blank Bio announces seed financing and strategic collaboration with PacBio” |
| Caris Life Sciences | Banner: “Caris Detect™ Multi-Cancer Early Detection Test Now Available.” |
| Ocean Genomics | No visible trust signal identified. |
| SOPHiA GENETICS | “Investors” navigation link signaling a publicly traded company. |
| BostonGene | Testimonial from Jorge Reis-Filho, MD, PhD, Chief of AI for Science Innovation, Enterprise AI Unit, AstraZeneca; the supplied report text is truncated after “alongsi”. |

### Trust ranking

1. BostonGene — 76
2. Caris Life Sciences — 54
3. Ocean Genomics — 52
4. Blank Bio — 48
5. SOPHiA GENETICS — 44

**Proof section builder — PRO:** [Build proof section](https://www.lazyweb.com/backlog?site=blank.bio#opt-trust-signals) to choose proof signals and receive copy and placement for a stronger trust section.

## CTA — 62, Fair

This category assesses whether the primary call to action earns the click through its copy, size, verb, and cost-feel.

![Blank Bio CTA comparison capture](https://zlfyzdmohcskkucuunmk.supabase.co/storage/v1/object/public/sites/growth-score/site/blank.bio.jpg?v=2026-09-22T20%3A34%3A28.322%2B00%3A00)

The primary CTA is **“Request early access.”** The report identifies these problems:

- It is styled as a text link rather than a button.
- “Request” feels like asking permission.
- It is visually weaker than the navigation’s “Contact” button.
- Its label does not imply a payoff.

### CTA ranking

1. Ocean Genomics — 72
2. BostonGene — 68
3. Blank Bio — 62
4. SOPHiA GENETICS — 55
5. Caris Life Sciences — 44

**CTA rewrite studio — PRO:** [Rewrite this CTA](https://www.lazyweb.com/backlog?site=blank.bio#opt-cta-writing) to generate primary and secondary CTA options grounded in Blank Bio’s offer and visitor objections.

## Mobile web — 62, Fair

This category assesses the phone experience as a first-class experience.

![Mobile web annotations on the Blank Bio capture](https://zlfyzdmohcskkucuunmk.supabase.co/storage/v1/object/public/sites/growth-score/site/blank.bio-mobile.jpg?v=2026-09-22T20%3A34%3A28.322%2B00%3A00)

1. **Request early access link:** The primary CTA is a thin text link, not a thumb-sized full-width button.
2. **News announcement banner:** Three stacked lines plus a “Read more” link take up the top of the fold and route the first tap to a press release.
3. **Read more link:** It is styled identically to the primary CTA, splitting attention between two underlined arrow links.

**Mobile fix plan — PRO:** [View mobile fixes](https://www.lazyweb.com/backlog?site=blank.bio#opt-mobile-web) to convert the findings into a prioritized implementation checklist.

## Value props — 68, Fair

This category asks whether the title, subtitle, and hero sell Blank Bio’s value.

### Blank Bio’s headline

> “RNA intelligence for precision oncology”

The supporting copy says:

> “Blank Bio enables pharma teams to identify the right patients for their clinical trials and predict how their disease will progress.”

### Working

- The subhead names the buyer: pharma teams.
- It names two concrete jobs: identifying the right patients for clinical trials and predicting how disease will progress.
- The PacBio news bar adds credibility.

### Could improve

- The H1 is a category label rather than an outcome.
- The fold contains no numbers or proof.
- There is no visual showing the product working.

### Value-proposition ranking

1. Caris Life Sciences — 76
2. BostonGene — 76
3. Blank Bio — 68
4. Ocean Genomics — 68
5. SOPHiA GENETICS — 62

## Information hierarchy — 72, Fair

This category assesses whether the design helps or inhibits the page’s intended message.

![Information hierarchy annotations on the Blank Bio desktop capture](https://zlfyzdmohcskkucuunmk.supabase.co/storage/v1/object/public/sites/growth-score/site/blank.bio.jpg?v=2026-09-22T20%3A34%3A28.322%2B00%3A00)

1. **Request early access link:** The primary CTA is a thin underlined text link and is visually weaker than the outlined Contact button above it.
2. **Contact button:** It is the only element styled like a button in the fold, so it outranks the primary conversion action.
3. **News banner Read more:** This top-of-page link is styled identically to the primary CTA and pulls first attention away from the page.
4. **About Us paragraphs:** A dense two-paragraph text wall enters the fold and dilutes the single-message hero.

**Layout priority plan — PRO:** [View layout plan](https://www.lazyweb.com/backlog?site=blank.bio#opt-information-hierarchy) to turn these callouts into a sequenced keep, move, merge, or remove plan.

## Competitors

These competitors are inferred from product, audience, and value proposition:

1. [Ocean Genomics — oceangenomics.com — 65](https://www.lazyweb.com/growth-score/site/oceangenomics.com)
2. [BostonGene — bostongene.com — 65](https://www.lazyweb.com/growth-score/site/bostongene.com)
3. Blank Bio — 62
4. [SOPHiA GENETICS — sophiagenetics.com — 58](https://www.lazyweb.com/growth-score/site/sophiagenetics.com)
5. [Caris Life Sciences — carislifesciences.com — 56](https://www.lazyweb.com/growth-score/site/carislifesciences.com)
6. [Tempus — tempus.com — failed](https://www.lazyweb.com/growth-score/site/tempus.com)

## Blank Bio’s stated landing-page content

The evaluated landing page describes Blank Bio as providing **RNA intelligence for precision oncology**. It says that Blank Bio enables pharma teams to identify suitable patients for clinical trials and predict disease progression. The evaluated mobile capture also includes a **Request early access** CTA, a PacBio financing and collaboration announcement, a **Contact** control, and an **About Us** section.

The report’s trust comparison includes screenshots of Blank Bio, BostonGene, and Caris Life Sciences. These images are comparative report material; they are not presented as Blank Bio’s business results.

---

[Read this page’s summary](https://www.lazyweb.com/api/public/v1/page-tldr?url=https%3A%2F%2Fwww.lazyweb.com%2Fyc-s25%2Fblank-bio&trace=t_bc7e1c4e5b07)

## Ask a follow-up about this page

Need a more specific answer? Ask the exact question you have. It returns a fresh, cited answer from Lazyweb’s knowledge base. No account or API key required.

Open this URL with your own question, URL-encoded. Only q is required. No account or setup.

`GET https://www.lazyweb.com/agent/faq?q={question}&trace=t_bc7e1c4e5b07`

[Tool guide and examples](https://www.lazyweb.com/agent-access) · [OpenAPI](https://www.lazyweb.com/api/public/v1/openapi.json) · [Page TLDR form](https://www.lazyweb.com/agent-tools/page-tldr?url=https%3A%2F%2Fwww.lazyweb.com%2Fyc-s25%2Fblank-bio). Opening a form does not execute a tool.